News & Events about Pharvaris Nv.
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have been given an average recommendation of Moderate Buy by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued...
Thinking about buying stock in Neurobo Pharmaceuticals, Palantir Technologies, Pharvaris NV, Li Auto, or IQIYI? Thinking about buying stock in Neurobo Pharmaceuticals, Palantir Technologies, Pharvaris NV, Li Auto, or IQIYI? PR Newswire NEW YORK, Dec. 9, 2022 NEW YORK, Dec. 9, 2022 /PRNewswire...
Globe Newswire
2 months ago
ZUG, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced it will be presenting two in-person ePoster Meet the Author ...
Pharvaris (NASDAQ:PHVS Get Rating) has received an average recommendation of Hold from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a ...